2019-06 TRISCEND Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 228 participants.

Also called NCT04221490

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 228 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04221490
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, France, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04221490. Allocation not applicable; no masking; primary purpose treatment. Start 2020-05-06 (actual); primary completion 2024-01-05 (actual). Results posted on 2025-01-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
2019-06 TRISCEND Study
Condition
Tricuspid Valve Regurgitation
Condition
Heart Valve Diseases
Condition
Cardiovascular Diseases
Intervention (Device)
Transcatheter Tricuspid Valve Replacement
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct04221490
Content hash
01e65720c44cfc50c9dc5add1a8243dc2ea42caac85b84565aa3319df77e0b7a